Free shipping over €250 · Tracked, discreet delivery in Europe

Complement C3 inhibitor

Pegcetacoplan

Empaveli · Aspaveli · Syfovre

Approved medicineNot yet reviewedPeptide

In short: A pegylated cyclic peptide that blocks complement C3. Approved for paroxysmal nocturnal haemoglobinuria and geographic atrophy.

Regulatory status

  1. Cosmetic ingredient
  2. Research compound
  3. In clinical trials
  4. Approved medicine

Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Common questions

Is Pegcetacoplan an approved medicine?

Approved medicine. Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.

How much human research is there on Pegcetacoplan?

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Does UU supply Pegcetacoplan?

No. It appears in the library for reference only, so the field can be read in one place.

More in Immune & airways

Back to the library
  • Researchuu

    KPV

    Alpha-MSH fragment

    Preclinical
  • Researchuu

    Thymosin alpha-1

    Thymic peptide

    Human trials
  • Researchuu

    Thymalin

    Thymic peptide preparation

    Early human data
  • Researchuu

    LL-37

    Antimicrobial peptide

    Early human data
  • Researchuu

    VIP

    Neuropeptide

    Human trials
  • Researchuu

    ARA-290

    Erythropoietin-derived peptide

    Early human data

The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.